Kite Pharma, Inc. (KITE) saw its loss widen to $73.95 million, or $1.49 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $27.44 million, or $0.63 a share. On the other hand, adjusted net loss for the quarter widened to $54.68 million, or $1.10 a share from a loss of $16.60 million or $0.38 a share, a year ago.
Revenue during the quarter surged 44.31 percent to $7.34 million from $5.09 million in the previous year period.
Operating loss for the quarter was $74.95 million, compared with an operating loss of $27.78 million in the previous year period.